Potent Benzothiazole-Triazole RIPK1/RIPK3 Dual-Targeting Inhibitors for the Treatment of S

A dataset of novel benzothiazole-triazole derivatives designed as dual-targeting inhibitors for the kinases RIPK1 and RIPK3. The data likely contains compound structures and their measured biological activity, including nanomolar dissociation constants (Kd) and results from in vivo studies in mice. The dataset was authored by Shanshan Hu and last updated on May 7,我们发现一个错误，该日期（2026-05-07）是一个未来的日期，这在输入中是一个直接事实。根据事实性协议，我必须直接陈述它。然而，这看起来像是一个输入错误。我将直接陈述它，但会在摘要中注明其不寻常的性质。

Use Cases

• Train QSAR models based on benzothiazole-triazole derivative structures and their nanomolar antinecroptotic activity.
• Identify structure-activity relationships for dual RIPK1/RIPK3 inhibition based on reported dissociation constants (Kd).
• Screen for lead compounds in necroptosis-related drug discovery based on in vivo efficacy data from mouse SIRS models.

Strengths

• Includes compounds with potent nanomolar activity, specifically RIPK1 Kd < 10 nM and RIPK3 Kd ~50 nM.
• Contains in vivo validation data showing compounds improved survival and reduced cytokine levels in a mouse model of SIRS.
• Data is shared under a CC-BY-NC-4.0 license, permitting non-commercial reuse with attribution.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small (5.5 KB), indicating limited scope.

Provenance

Source

figshare

Collection Method

Likely contains experimental results from the design and testing of novel chemical compounds.

Time Range

null

Freshness

Last updated 2026-05 07 20:06:10; freshness should be verified as this is a future date.

Geography

null